Asian Companies to Collaborate on Type 1 Antibody Treatment

| Jan 10, 2014

Two Asian companies--BioLineRx of Israel and JHL Biotech of Taiwan--have agreed to collaborate on the development and marketing of BL-9020, a monoclonal antibody that could become a significant means of treatment for early-stage type 1 diabetes.

BL-9020 targets Natural Killer receptor cells in the immune system which play a key role in attacking pancreatic beta cells, eventually leading to the onset of full-blown type 1 diabetes. The Natural Killer cells, called NKp-46, specifically target those insulin-producing cells.

Development of an effective application of BL-9020 could preserve remaining beta cells, and either delay or even prevent the need for frequent insulin use by type 1s. Studies with lab mice manifesting type 1 have shown that BL-9020 is effective during the so-called "honeymoon period" when the disease has not yet completely shut down insulin production.

Both biopharmaceutical companies will split the tasks of developing and commercializing an eventual Bl-9020 product, with JHL Biotech possessing global manufacturing rights and exclusive marketing rights in China and Southeast Asia. BioLineRx will have development and commercialization rights for the rest of the world.

JHL Biotech has said it will adhere to FDA guidelines and regulations as it develops the treatment. No estimates were given as to when human trials of BL-9020 might begin.

Click Here To View Or Post Comments

Categories: Beta Cells, BioLineRx, BL-9020 Monoclonal Antibody, Honeymoon Period, JHL Biotech, Natural Killer Cells , NKp-46, Type 1

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.